Study Overview: This study looks at whether medicines called encorafenib and cetuximab help stop colon cancer from coming back after surgery and usual chemotherapy in patients with a specific gene change, called BRAF mutation. Encorafenib blocks certain enzymes in cancer cells to stop them from growing. Cetuximab is a monoclonal antibody that attaches to a protein on cancer cells, which may help stop them from growing. The study compares this treatment to usual observation after surgery and chemotherapy.

• Duration: The study involves regular visits and tests, including blood samples and scans.
• Treatment or Observation: Participants will either receive the medicines or be observed as per usual care.
• Eligibility: Participants must have stage II or III colon cancer with a BRAF mutation and have completed specific chemotherapy.

Participants must be adults over 18, not pregnant or nursing, and meet specific health criteria. The study aims to find out if the new treatment is better at preventing cancer from returning compared to usual care. If you meet the criteria and are considering joining, talk with your doctor about the potential risks and benefits.